Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P7 is a processed pseudogene of the ribosomal protein L21 gene (RPL21). Pseudogenes like RPL21P7 lack the capacity to encode functional protein products due to accumulated mutations or lack of regulatory elements. While the parent gene, RPL21, codes for a structural constituent of the ribosome’s 60S large subunit and plays a critical role in protein synthesis[1][3], RPL21P7 itself does not encode a functional protein and has no known biological or therapeutic activity. According to the HUGO Gene Nomenclature Committee, RPL21P7 is an approved pseudogene locus, not a coding gene[2]. There is no evidence in the scientific literature to support a direct function, involvement in disease, clinical biomarker use, or druggability of RPL21P7.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L21 pseudogene 7 (RPL21P7).